GlassScriptPhysician profile
Jessica L Lucente
NPI 1356441406
$2,007.43
in general payments reported to CMS, 2019-2025
21 companies · $966 in 2025
The $966 reported for 2025 was more than what 80% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $130 · 2024: $911 · 2025: $966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,007.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,007.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $396.47 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $395.36 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $220.21 | 2024-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $200.53 | 2023-2025 | Trelegy Ellipta |
| Aimmune Therapeutics, INC. | $107.71 | 2025 | Zenpep |
| Abbott Laboratories | $76.32 | 2023-2025 | Freestyle Libre 3, Proclaim, Octrode |
| Corcept Therapeutics | $72.73 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.91 | 2023-2025 | Jardiance, Tradjenta |
| Lilly USA, LLC | $71.12 | 2024-2025 | Mounjaro, Zepbound, Trulicity |
| Eisai INC. | $64.51 | 2024-2025 | |
| Abbvie INC. | $55.31 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $54.58 | 2024-2025 | |
| Dexcom, INC. | $34.99 | 2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $32.72 | 2023-2025 | Cologuard Collection Kit |
| Medtronic, INC. | $29.52 | 2024 | Interstim |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $25.58 | 2025 | Inspire |
| Otsuka America Pharmaceutical, INC. | $23.61 | 2025 | Rexulti |
| Cequr Corporation | $23.11 | 2025 | Cequr Simplicity |
| Sandoz INC. | $18.57 | 2025 | |
| Tolmar, INC. | $17.30 | 2025 | Jatenzo |
| Amneal Pharmaceuticals LLC | $15.27 | 2025 | Unithroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Lucente listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.